Uptake of evidence-based statin therapy among atrial fibrillation patients in China

Xia, Shi-jun; Du, Xin; Li, Chao; Wu, Jia-hui; Tang, Ri-bo; Chang, San-shuai; Guo, Xue-yuan; Yu, Rong-hui; Long, De-yong; Bai, Rong; Liu, Nian; Sang, Cai-hua; Li, Song-nan; Liu, Xiao-hui; Pan, Jian-hong; Dong, Jian-zeng; Lip, Gregory Y.h.; Ma, Chang-sheng

DOI:

[10.1016/j.ijcard.2016.06.113](https://doi.org/10.1016/j.ijcard.2016.06.113)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Xia, S, Du, X, Li, C, Wu, J, Tang, R, Chang, S, Guo, X, Yu, R, Long, D, Bai, R, Liu, N, Sang, C, Li, S, Liu, X, Pan, J, Dong, J, Lip, GYH & Ma, C 2016, 'Uptake of evidence-based statin therapy among atrial fibrillation patients in China: a report from the CAFR (Chinese Atrial Fibrillation Registry) Study', *International Journal of Cardiology*, vol. 220, pp. 284-289. <https://doi.org/10.1016/j.ijcard.2016.06.113>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Accepted Manuscript

Uptake of Evidence-based Statin Therapy among Atrial Fibrillation Patients in China: A report from the CAFR (Chinese Atrial Fibrillation Registry) Study

Shi-jun Xia, Xin Du, Chao Li, Jia-hui Wu, Ri-bo Tang, San-shuai Chang, Xue-yuan Guo, Rong-hui Yu, De-yong Long, Rong Bai, Nian Liu, Cai-hua Sang, Song-nan Li, Xiao-hui Liu, Jian-hong Pan, Jian-zeng Dong, Gregory Y.H. Lip, Chang-sheng Ma

PII: S0167-5273(16)31122-6
DOI: doi: [10.1016/j.ijcard.2016.06.113](https://doi.org/10.1016/j.ijcard.2016.06.113)
Reference: IJCA 22741

To appear in: *International Journal of Cardiology*

Received date: 23 March 2016
Revised date: 4 June 2016
Accepted date: 21 June 2016

Please cite this article as: Xia Shi-jun, Du Xin, Li Chao, Wu Jia-hui, Tang Ri-bo, Chang San-shuai, Guo Xue-yuan, Yu Rong-hui, Long De-yong, Bai Rong, Liu Nian, Sang Cai-hua, Li Song-nan, Liu Xiao-hui, Pan Jian-hong, Dong Jian-zeng, Lip Gregory Y.H., Ma Chang-sheng, Uptake of Evidence-based Statin Therapy among Atrial Fibrillation Patients in China: A report from the CAFR (Chinese Atrial Fibrillation Registry) Study, *International Journal of Cardiology* (2016), doi: [10.1016/j.ijcard.2016.06.113](https://doi.org/10.1016/j.ijcard.2016.06.113)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Uptake of Evidence-based Statin Therapy among Atrial Fibrillation Patients in China:

A report from the CAFR (Chinese Atrial Fibrillation Registry) Study

All authors:

Shi-jun Xia¹, MD; Xin Du¹, MD; Chao Li¹, MD; Jia-hui Wu¹, MD; Ri-bo Tang¹, MD;
 San-shuai Chang¹, MD; Xue-yuan Guo¹, MD; Rong-hui Yu¹, MD; De-yong Long¹, MD;
 Rong Bai¹, MD; Nian Liu¹, MD; Cai-hua Sang¹, MD; Song-nan Li¹, MD; Xiao-hui Liu¹,
 MD; Jian-hong Pan², MPH; Jian-zeng Dong¹, MD; Gregory Y.H. Lip³, MD; Chang-sheng
 Ma¹, MD

¹ Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,
 National Clinical Research Centre for Cardiovascular Diseases, Beijing, China;

² Peking University Clinical Research Institute, Beijing, China;

³ University of Birmingham Centre for Cardiovascular Sciences, City Hospital,
 Birmingham, UK.

Co-corresponding author:

Professor Chang-sheng Ma

Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Mailing address: No 2 Anzhen Road, Chaoyang District Beijing China 100029

Fax number: 8610-64456078

Telephone number: 8613901357404

Email address: chshma@vip.sina.com

Professor Xin Du

Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Mailing address: No 2 Anzhen Road, Chaoyang District Beijing China 100029

Fax number: 8610-64456078

Telephone number: 8613370103558

Email address: duxinheart@sina.com

Funding sources

This study was supported by a grant (2013BAI09B02) from the Ministry of Science and Technology of the People's Republic of China and grants (ZYLX201302, D111100003011004, and D131100002313001) from Beijing Municipal Commission of Science and Technology.

The construction of the CAFR was also supported by grants from Bristol-Myers Squibb (BMS), Pfizer, Johnson & Johnson, Boehringer-Ingelheim (BI), and Bayer.

Disclosures

Chang-sheng Ma has received honoraria from Bristol-Myers Squibb (BMS), Pfizer, Johnson & Johnson, Boehringer-Ingelheim (BI) and Bayer for giving lectures.

Jian-zeng Dong has received honoraria from Johnson & Johnson for giving lectures.

Gregory Y.H. Lip: Consultant for Bayer/Janssen, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo.

Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche

and Daiichi-Sankyo

Other authors report no conflicts of interest.

Key Words: atrial fibrillation, evidence-based statin therapy, China

ABSTRACT

Background—Atrial fibrillation (AF) is associated with increased incidence of cardiovascular disease, and hence, statin therapy is indicated in majority of AF patients.

Methods and results—We analyzed data from the Chinese Atrial Fibrillation Registry (CAFR) involving 11496 AF patients from 2011 to 2014. Practice patterns of statin therapy and factors associated with statin underuse were analyzed.

Based on the 2013 ACC/AHA cholesterol management guidelines, statins should be recommended for 67.4% (7720/11461) of AF participants in CAFR, but only 43.4% (3352/7720) with appropriate indications were taking statins. Statin underuse in AF patients was independently associated with male sex, tertiary hospital treatment, outpatient attendance, and absence of 'high risk' cardiovascular risk factors (overweight, diabetes, coronary heart disease, stroke/transient ischemic attack/peripheral embolism and hypertension).

Conclusions—A high proportion of Chinese AF patients had indications for statin

therapy. Evidence-based statin prescribing was suboptimal in this population. Greater efforts should be made to improve a holistic approach to cardiovascular risk management in the Chinese AF population.

Introduction

Atrial Fibrillation (AF) is the most common cardiac arrhythmia, with 33.5 million prevalent and additional 5 million incident AF cases being reported in 2010 worldwide.[1] AF is consistently associated with a higher risk of morbidity and mortality, especially from cardiovascular conditions.[2, 3] In addition, the presence of cardiovascular comorbidities and risk factors are not uncommon in AF patients. Due to high prevalence of cardiovascular risk factors among AF patients, risk of adverse cardiovascular outcomes is also substantially higher in this group of patients.[4-6]

In the Action in Diabetes and Vascular Disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study, for example, AF was found to be associated with substantially increased risk of death and cardiovascular events in patients with type 2 diabetes.[7] In the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, AF patients had almost 2-fold higher risk of myocardial infarction [hazard ratio 1.96, 95% confidence interval (CI), 1.52-2.52] after adjusting confounding factors.[8] More recently, incident AF was found to be associated with

increased risk of sudden cardiac death (SCD) and non-SCD in the general population.[9] Despite this high cardiovascular risk, management of risk factors is sometimes neglected in practice, given that stroke prevention is the most feared complication of AF and much focus is directed on oral anticoagulation therapy.

Statin therapy can substantially reduce the risk of cardiovascular disease.[10] Given their high cardiovascular risk, treatment with statins may bring larger absolute risk reduction for AF patients. As the public health burden of AF in China is increasing, insights into the pattern of statin usage in AF patients will provide important information for future healthcare quality improvement.

The ongoing Chinese Atrial Fibrillation Registry (CAFR) recruited AF patients from 31 hospitals located in urban and semi-urban areas of Beijing. In this report from CAFR, we studied the use of statin therapy in this population and explored factors associated with statin underuse in clinical practice, amongst Chinese AF patients.

Methods

Study design and participants

The Chinese Atrial Fibrillation Registry (CAFR) is a prospective, multicenter, hospital-based, ongoing registry study of patients diagnosed with AF in Beijing, China.

The majority of tertiary and nontertiary hospitals providing a clinical service of AF

management in Beijing participated in this registry study. Data collected between August 2011 and July 2014 from 31 hospitals were used for analyses.

Trained personnel including doctors from tertiary and nontertiary hospitals enrolled unselected eligible AF outpatients and inpatients from their daily practices. Abstracted data were submitted to the CAFR registry website. Eligible patients were those aged ≥ 18 years, with AF documented via either electrocardiogram (ECG) or Holter within the past 6 months. AF was diagnosed by local investigator via the baseline 12-lead ECGs or Holter recordings. Written informed consent was obtained from each patient. Those patients with transient and reversible AF, suffering from other diseases with a life expectancy < 1 year, diagnosed with rheumatic mitral stenosis or having mitral valve prostheses were excluded.

Data collection

Patients' characteristics information, including socio-demographic data (age, gender, level of education, and medical insurance status), medical history [history of congestive heart failure, hypertension, diabetes, hyperlipidemia, prior stroke/transient ischemic attack (TIA)/peripheral thromboembolism, established coronary heart disease (any history of myocardial infarction, percutaneous coronary intervention or coronary artery bypass graft surgery), hyperlipidemia, prior bleeding], cardiovascular risk factors (smoking, alcohol consumption and body mass index), results of physical examinations, results of the latest laboratory tests, including liver

and renal function, blood glucose and cholesterol levels, tested within 1 year or at the time of enrollment, results of electrocardiogram and echocardiogram, and medical therapies received were collected.

Definition of population with indications for statins

According to the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline, statins use was recommended for four subgroups of patients: adults with atherosclerotic cardiovascular disease, adults with LDL cholesterol $>190\text{mg/dL}$, adults 40-79 years old with LDL cholesterol 70-189 mg/dL and diabetes, and adults with a 10-year predicted risk for atherosclerotic cardiovascular disease (ASCVD) $\geq 5\%$. [10]

In this study, ASCVD was defined as positive history of acute coronary syndromes, myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke/TIA, or peripheral arterial disease presumed to be of atherosclerotic origin. 10-year risk of ASCVD was predicted with a simplified point score model as recommended by Chinese guidelines. [11, 12] The algorithm used in this study is provided in the appendix Figure 1.

Statistical analysis

Categorical variables were shown as n(%), whereas continuous variables are shown as mean (standard deviation, SD). Continuous variables were compared using either

the unpaired T-test or the Mann-Whitney U test, whereas categorical variables were compared using the Chi-square test. For the analysis of factors associated with non-use of statins in AF patients who have indication(s), a univariate logistic regression was first conducted by using each baseline variable as a covariate. A logistic regression model was then applied to include all the significant covariates identified in the univariate analysis. A stepdown method was used to determine the final model of the logistic regression. To investigate whether the rate of statin usage differed significantly among hospitals after considering the differences in patients' characteristics, we also fitted a generalized linear mixed model with hospital included as a random effect and tested whether the variance for the random effect was significantly different from zero. The results were shown in appendix. A *P* value <0.05 was considered statistically significant. All analyses were conducted using SAS software, version 9.2.

Ethical approval

The CAFR was reviewed and approved by the Ethics committee of Beijing Anzhen Hospital.

Results

We included 11496 patients with AF (average age 65.8 ± 12.0 years, 40.4% female), where the prevalence of patients with history of hypertension, congestive heart failure, diabetes, stroke/TIA/peripheral embolism, established coronary heart diseases and hyperlipidemia were 66.1%, 18.9%, 24.5%, 17.0%, 17.8% and 27.0%,

respectively (Table 1). More than half (52.9%) of patients had paroxysmal AF, 38.3% with persistent AF, and the rest with newly diagnosed AF. The majority of enrolled patients (92.0%) were totally or partially covered by medical insurance. Compared to participants enrolled from tertiary hospitals, those enrolled from nontertiary hospitals were older, more likely to have comorbidities, and more likely to be smokers, had lower education status and permanent AF (Table 1).

Statin usage among those with indications

Overall, 67.4% (7720/11461) of AF patients had indication(s) for statin therapy while only 43.4% (3352/7720) patients with indication(s) were taking statin. Usage of statin varied among patients with different indications (Table 2): 57.8% (2022/3500) of those patients with a history of ASCVD were taking statin.

For those with LDL-C $\geq$ 190 mg/dL, 58.1% (36/62) patients were taking statin. In contrast, only 37.6% (303/807) of patients aged 40-79 years old with diabetes and LDL cholesterol=70-189 mg/dL and 29.6% (991/3351) of patients who had predicted 10-year-ASCVD risk $\geq$ 5% were taking statin. Of note, 20.6% (771/3741) of AF patients with no guideline recommended indications for statin use were taking it. Among patients with statin indications, the proportion of statin usage varied from 32% to 74% in tertiary hospitals and from 33% to 75% in nontertiary hospitals (Figure 1).

Factors associated with statin usage in AF patients

After adjusting covariates that may impact the use of statins, underuse in AF patients were found to be independently associated with male sex [odds ratio (OR) 1.15, 95%CI 1.03-1.29] and tertiary hospital treatment (OR 1.99, 95%CI 1.70-2.31), while inpatients treatment (OR 0.70, 95%CI 0.63-0.79), BMI $\geq$ 28 (OR 0.80, 95%CI 0.70-0.91) and comorbidities including history of diabetes, CHD, stroke/TIA/peripheral embolism and hypertension were associated with higher likelihood of statin use. ORs of statin underuse among patients with these comorbidities were 0.74 (95%CI 0.66-0.83), 0.26 (95%CI 0.23-0.30), 0.59 (95%CI 0.52-0.67) and 0.60 (95%CI 0.53-0.69) respectively. (Table 3)

In subgroups of patients treated in tertiary and nontertiary hospitals, factors associated with non-use of statins were also analyzed by the proc glimmix model which included hospital type as a random effect, and showed consistent results (intercept *P* among tertiary hospitals: 0.3396, non-tertiary hospital: 0.2888). [see Appendix Table 1-2]

Discussion

In this contemporary large registry study of statin therapy use in patients with AF we found that statin was greatly underused in AF patients, especially in those with a 10-year predicted risk for ASCVD $\geq$ 5% and those aged 40-79 years old with LDL cholesterol 70-189 mg/dL and diabetes. Conversely a substantial proportion of AF

patients with no indication for statins were prescribed these drugs.

Several large cohort studies have noticed increased risk of adverse cardiovascular outcomes beyond stroke in AF patients, that is, cardiovascular events including heart failure, myocardial infarction, etc.[6, 13, 14] However, the importance of preventing cardiovascular events is perhaps under-emphasized in current practice. ASCVD is not an uncommon comorbidity in AF patients.[15-17] On the other hand, AF patients already receiving anticoagulation therapy still suffer from a relative high risk of ASCVD events.[14, 18] Given the increased risk of AF-associated mortality and cardiovascular complications, especially the bidirectional relationship between AF and ASCVD,[8, 19] a comprehensive and holistic management approach of all cardiovascular risk factors in AF patients is of vital importance.

Much of the focus of AF management is directed towards stroke prevention with antithrombotic therapy, as well as rate or rhythm control. Less attention is paid to the importance of cardiovascular risk factor modification. Indeed, suboptimal statin usage was observed in our study, whereby over 65% of Chinese AF patients had statin indications while less than half of them were prescribed statin. Although the underuse of evidence-based cardiac prevention therapy has been noticed in patients with coronary heart disease [20-22] and initiatives have been launched to improve this, suboptimal treatment among patients with AF has not yet got enough attention. Aside from optimal statin usage, optimal management of traditional risk factors like

hypertension and diabetes, management of obesity and overweight, leading healthy lifestyle are of equal importance in reducing cardiovascular risk and AF management. [23] However, it is reported that only a minority of patients received indicated therapies for their comorbidities and nearly half patients hadn't have their blood pressure controlled.[24] Importantly, AF patients whose predicted 10-year-ASCVD risk $\geq 5\%$ in our study were least likely to receive any statin, reflecting the practice pattern of statin use which is more likely to be based on single disease rather than considering the complexity of all comorbidities and risk factors. Over-prescribing was evident in more than 20% of AF patients without indication for statins.

Interestingly, we observed a statin prescription "paradox" in different level hospitals. Patients treated in tertiary hospitals were less likely to receive guideline-indicated statins. There are several possible underlying reasons for this prescription paradox. First, doctors in tertiary hospitals are busier and looking after more patients so that they had more limited time to consider the importance of statin therapy. Second, doctors in tertiary hospitals focused more on anticoagulation therapy and even more invasive and expensive interventions such as ablation therapy, whilst statin therapy is ignored. After adjusting for covariates, we found outpatients and male patients to be less likely to be prescribed statin. This is in line with our hypothesis that doctors in the outpatients department were less likely to have enough time to communicate with patients about the necessity of taking statins. Moreover, statin underuse was associated with fewer comorbid conditions and less overweight, which again

suggests that doctors are likely to ignore statin therapy in those patients with multiple moderate increased risk factors while great increased global cardiovascular risk. We didn't find medical insurance coverage was a risk factor for statin under prescription in this study. One possible explanation is that majority of Beijing residents are covered by "medical insurance for urban residents" or "medical insurance for urban employees". Out-of-pocket expense is about 30% of the medical fee for out-of-hospital medication. For rural residents, although only 50% of in-hospital cost can be reimbursed by "new rural cooperative medical care", the costs of statins are not unaffordable as generic statins are less expensive.

Limitations

The study population was composed of AF patients recruited from hospitals in Beijing, China's capital, and might not fully represent the whole AF population in China. Since majority of the recruiting sites were high-level medical centers located in urban areas, we can assume that statin use may be poorer in other areas of the country, especially in rural areas. The importance of statin therapy and treat the AF patient as a whole person rather than a single medical problem should be more emphasized in related guidelines. Reasons for not prescribing statin in AF population were not collected and thus detailed analysis cannot be provided, including the proportion with drug intolerance. The majority of our patients were covered by health insurance and thus, drug costs are not likely to account for the substantial proportion with non-use of statins.

Conclusions

A high proportion of Chinese AF patients had indications for statin therapy. Evidence-based statin prescribing was suboptimal in this population. Greater efforts should be made to improve a holistic approach to cardiovascular risk management in the Chinese AF population.

Funding sources

This study was supported by a grant (2013BAI09B02) from the Ministry of Science and Technology of the People's Republic of China and grants (ZYLX201302, D111100003011004, and D131100002313001) from Beijing Municipal Commission of Science and Technology.

The construction of the CAFR was also supported by grants from Bristol-Myers Squibb (BMS), Pfizer, Johnson & Johnson, Boehringer-Ingelheim (BI), and Bayer.

Disclosures

Chang-sheng Ma has received honoraria from Bristol-Myers Squibb (BMS), Pfizer, Johnson & Johnson, Boehringer-Ingelheim (BI) and Bayer for giving lectures.

Jian-zeng Dong has received honoraria from Johnson & Johnson for giving lectures.

Gregory Y.H. Lip: Consultant for Bayer/Janssen, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo.

Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo

Other authors report no conflicts of interest.

References

- [1] Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation*. 2014;129:837-47.
- [2] Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation*. 1998;98:946-52.
- [3] Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. *Eur Heart J*. 2007;28:1962-7.
- [4] Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, Buring JE, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. *JAMA*. 2011;305:2080-7.
- [5] Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. *Circulation*. 2007;115:3050-6.
- [6] Piccini JP, Hammill BG, Sinner MF, Hernandez AF, Walkey AJ, Benjamin EJ, et al. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. *Eur Heart J*. 2014;35:250-6.
- [7] Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. *Eur Heart J*.

2009;30:1128-35.

[8] Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, et al. Atrial fibrillation and the risk of myocardial infarction. *JAMA Intern Med.* 2014;174:107-14.

[9] Chen LY, Sotoodehnia N, Buzkova P, Lopez FL, Yee LM, Heckbert SR, et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. *JAMA Intern Med.* 2013;173:29-35.

[10] Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation.* 2014;129:S1-45.

[11] Chinese Society of Cardiology of Chinese Medical Association EBoCJoC. [Chinese guidelines for prevention of cardiovascular diseases]. *Zhonghua Xin Xue Guan Bing Za Zhi.* 2011;39:3-22.

[12] Wu Y, Liu X, Li X, Li Y, Zhao L, Chen Z, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. *Circulation.* 2006;114:2217-25.

[13] Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, et al. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands. *J Am Coll*

Cardiol. 2015;66:1000-7.

[14] Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. *Circulation*. 2013;128:237-43.

[15] Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. *Circulation*. 2009;119:606-18.

[16] Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. *Eur Heart J*. 2009;30:1038-45.

[17] Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *JAMA*. 1994;271:840-4.

[18] Polimeni L, Perri L, Saliola M, Basili S, Violi F. The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. *Intern Emerg Med*. 2010;5:91-4.

[19] Soliman EZ, Lopez F, O'Neal WT, Chen LY, Bengtson L, Zhang ZM, et al. Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*. 2015;131:1843-50.

[20] Tang L, Patao C, Chuang J, Wong ND. Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey

2007-2010). Am J Cardiol. 2013;112:1126-32.

[21] Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636-48.

[22] Maddox TM, Borden WB, Tang F, Virani SS, Oetgen WJ, Mullen JB, et al. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;64:2183-92.

[23] Miller JD, Aronis KN, Chrispin J, Patil KD, Marine JE, Martin SS, et al. Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation. J Am Coll Cardiol. 2015;66:2899-906.

[24] Hess PL, Kim S, Piccini JP, Allen LA, Ansell JE, Chang P, et al. Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med. 2013;126:625-32 e1.

Figure Legends

Figure 1. Statin use in different hospitals amongst AF patients with indications.

Inclusion of at least 50 patients from each participating hospital was sought.

Table 1. Baseline characteristics of the patients.

Characteristics	Tertiary (N=10029)	Nontertiary (N=1467)	Overall (N=11496)
Age (mean $\pm$ SD)	65.0 $\pm$ 12.0	70.8 $\pm$ 10.0	65.8 $\pm$ 12.0
Gender, male	6050/10029 (60.3)	796/1467 (54.3)	6846/11496 (59.6)
Congestive heart failure	1456/10029 (14.5)	718/1467 (48.9)	2174/11496 (18.9)
Hypertension	6432/10018 (64.2)	1157/1467 (78.9)	7589/11485 (66.1)
Diabetes	2349/10029 (23.4)	464/1467 (31.6)	2813/11496 (24.5)
Prior Stroke/TIA/Peripheral embolism	1597/10028 (15.9)	356/1467 (24.3)	1953/11495 (17.0)
Prior bleeding	472/10028 (4.7)	57/1467 (3.9)	529/11495 (4.6)
Hyperlipidemia	2620/10002 (26.2)	471/1459 (32.3)	3091/11461 (27.0)
Established CHD*	1680/10028 (16.8)	366/1466 (25.0)	2046/11494 (17.8)
Smoking			
Current	1606/9968 (16.1)	242/1461 (16.6)	1848/11429

			(16.2)
Former	1604/9968 (16.1)	332/1461 (22.7)	1936/11429 (16.9)
None	6758/9968 (67.8)	887/1461 (60.7)	7645/11429 (66.9)
Alcohol			
Current	1901/9958 (19.1)	235/1461 (16.1)	2136/11419 (18.7)
Former	1177/9958 (11.8)	205/1461 (14.0)	1382/11419 (12.1)
None	6880/9958 (69.1)	1021/1461 (69.9)	7901/11419 (69.2)
BMI (mean±SD)	25.4±3.7	25.3±3.8	25.4±3.7
Type of AF			
First time of diagnose	691/10029 (6.9)	323/1467 (22.0)	1014/11496 (8.8)
Paroxysmal	5620/10029 (56.0)	463/1467 (31.6)	6083/11496 (52.9)
Persistent	3718/10029 (37.1)	681/1467 (46.4)	4399/11496 (38.3)
Completed higher education	3032/8281 (36.6)	117/1450 (8.1)	3149/9731 (32.4)

Types of health

insurance

None	825/10029 (8.2)	93/1467 (6.3)	918/11496 (8.0)
Partially	7906/10029 (78.8)	1284/1467 (87.5)	9190/11496 (79.9)
100%	1298/10029 (12.9)	90/1467 (6.1)	1388/11496 (12.1)

Type of healthcare

Outpatients	4923/10029 (49.1)	377/1467 (25.7)	5300/11496 (46.1)
Inpatients	5106/10029 (50.9)	1090/1467 (74.3)	6196/11496 (53.9)

Values are n/N (%), unless otherwise indicated.

BMI indicates body mass index; TIA, transient ischemic attack; CHD, coronary heart disease;

* Established Coronary heart disease includes history of myocardial infarction, history of percutaneous coronary intervention and history of coronary artery bypass grafting

Table 2. Statin use and prevalence of indications for statin use among CAFR Study participants

Participants Subgroups	Tertiary		Nontertiary		<i>P</i>
	With indication	Taking statin	With indication	Taking statin	
History of ASCVD*	2881	1619/2881 (56.2%)	619	403/619 (65.1%)	<0.001
LDL-C ≥190 mg/dL	56	32/56 (57.1%)	6	4/6 (66.7%)	0.653
Diabetes, LDL-C 70-189 mg/dL, 40-75y	697	241/697 (34.6%)	110	62/110 (56.4%)	<0.001
10-year-ASCVD risk ≥5%	2895	777/2895 (26.8%)	456	214/456 (46.9%)	<0.001
Any indication for statin therapy	6529	2669/6529 (40.9%)	1191	683/1191 (57.4%)	<0.001
No indication for statin therapy	3469	660/3469 (19.0%)	272	111/272 (40.8%)	<0.001

* History of atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin.

LDL-C indicate low-density lipoprotein cholesterol.

Table 3. Factors associated with no statin use in AF patients who have indications

Characteristics	n/N(%)	Crude OR (95%CI)	Adjusted OR (95%CI)
Age			
<75	2952/5161 (57.2)	1.00 (reference)	-
≥75	1416/2570 (55.1)	0.92 (0.84,1.01)	-
Gender			
Female	2678/4578 (58.5)	1.00 (reference)	1.00 (reference)
Male	1690/3159 (53.5)	1.23 (1.12,1.35)	1.15 (1.03,1.29)
Education			
Higher education	1193/1949 (61.2)	1.00 (reference)	-
Lower education	2529/4607 (54.9)	0.77 (0.69,0.89)	-
Hospital level			
Nontertiary	508/1191 (42.6)	1.00 (reference)	1.00 (reference)

Characteristics	n/N(%)	Crude OR (95%CI)	Adjusted OR (95%CI)
Tertiary	3860/6529 (59.1)	1.94 (1.72,2.20)	1.99 (1.70,2.31)
Diabetes			
No	3091/5178 (59.7)	1.00 (reference)	1.00 (reference)
Yes	1277/2559 (49.9)	0.67 (0.61,0.74)	0.74 (0.66,0.83)
BMI			
BMI < 28	3107/5348 (58.1)	1.00 (reference)	1.00 (reference)
BMI ≥ 28	781/1491 (52.4)	0.79 (0.71,0.89)	0.80 (0.70,0.91)
Established CHD			
No	3713/5685 (65.3)	1.00 (reference)	1.00 (reference)
Yes	654/2044 (32.0)	0.25 (0.22,0.28)	0.26 (0.23,0.30)
Stroke/TIA/Peripheral embolism			
No	3406/5783 (58.9)	1.00 (reference)	1.00 (reference)
Yes	962/1951 (49.3)	0.68 (0.61,0.75)	0.59 (0.52,0.67)

Characteristics	n/N(%)	Crude OR (95%CI)	Adjusted OR (95%CI)
Hypertension			
No	1254/1855 (67.6)	1.00 (reference)	1.00 (reference)
Yes	3107/5873 (52.9)	0.54 (0.48,0.60)	0.60 (0.53,0.69)
Congestive heart failure			
No	3551/5968 (59.5)	1.00 (reference)	-
Yes	817/1765 (46.3)	0.59 (0.53,0.65)	-
Health insurance			
100% covered	608/1042 (58.3)	1.00 (reference)	-
Partially covered	3434/6154 (55.8)	0.91 (0.80,1.04)	-
None	326/541 (60.3)	1.09 (0.89,1.34)	-
Smoking			
No	3672/6511 (56.4)	1.00 (reference)	-
Yes	678/1181 (57.4)	1.04 (0.92,1.18)	-
Alcohol			

Characteristics	n/N(%)	Crude OR (95%CI)	Adjusted OR (95%CI)
No	3562/6384 (55.8)	1.00 (reference)	-
Yes	782/1299 (60.2)	1.21 (1.07,1.36)	-
Form of treatment			
Outpatients	2225/3532 (63.0)	1.00 (reference)	1.00 (reference)
Inpatients	2143/4202 (51.0)	0.61 (0.56,0.67)	0.70 (0.63,0.79)

BMI indicates body mass index; TIA, transient ischemic attack; CHD, coronary heart disease.

Figure 1